Efficient Production of Dual Recombinant Adeno-Associated Viral Vectors for Factor VIII Delivery
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viral (rAAV) vectors have gained attention for human gene therapy because of their high safety and clinical efficacy profile. For factor VIII gene delivery, splitting the coding region between two AAV vectors remains a viable strategy to avoid the packaging capacity limitation (∼5.0 kb). However, it is time-consuming and labor-intensive to produce two rAAV vectors in separate batches. Here we demonstrated successful production of dual rAAV vectors for hemophilia A gene therapy in a single preparation. When the AAV vector plasmids carrying the human factor VIII heavy chain (hHC) and the light chain (hLC) expression cassettes were cotransfected into 293 cells along with the AAV rep&cap and mini-adenovirus helper plasmids, both rAAV-hHC and rAAV-hLC were produced at the desired ratio and in high titer. Interestingly, the rAAV-hHC vectors always yielded higher titers than rAAV-hLC vectors as a result of more efficient replication of rAAV-hHC genomes. The resulting vectors were effective in transducing the tissue culture cells in vitro. When these vectors were administered to hemophilia A mice, factor VIII was detected in the mouse plasma by both the activated partial thromboplastin time assay and enzyme-linked immunosorbent assay. The functional activity as well as the antigen levels of secreted factor VIII were similar to those of vectors produced by the traditional method. The dual-vector production method has been successfully extended to both AAV2 and AAV8 serotypes. In conclusion, cotransfection of vector plasmids presents an efficient method for producing dual or multiple AAV vectors at significantly reduced cost and labor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“R ecombinant adeno-associated viral (rAAV) vectors have shown great promise for gene therapy because of their safety and clinical efficacy as demonstrated in a number of phase I/II clinical trials (Muramatsu et al ., 2010; Nathwani et al ., 2011; Bowles et al ., 2012; Ferreira et al ., 2013).”
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · cited 1×
“Recently, the first gene therapy product, Glybera, utilizing rAAV1 as a vector, was approved by the European Commission for treatment of a rare disease, lipoprotein lipase deficiency (Miller, 2012; Ferreira et al., 2013; Gaudet et al., 2013).”
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344 · cited 1×
“R ecombinant adeno-associated viral (rAAV) vectors have shown great promise for gene therapy because of their safety and clinical efficacy as demonstrated in a number of phase I/II clinical trials (Muramatsu et al ., 2010; Nathwani et al ., 2011; Bowles et al ., 2012; Ferreira et al ., 2013).”
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305 · cited 2×
“An alternative method to address packaging limitation is to split the oversized transgenes into two or more segments (Burton et al ., 1999; Yan et al ., 2000, 2007; Duan et al ., 2001; Chao et al ., 2002; Lai et al ., 2005, 2006; Ghosh et al ., 2006, 2011).”
McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278 · cited 2×
“…et al ., 2005; Yan et al ., 2013), Duchenne muscular dystrophy (Wang et al ., 2000; Goncalves et al ., 2005; Koo et al ., 2013), hemophilia A (Gnatenko et al ., 1999; McIntosh et al ., 2013; Siner et al ., 2013), and other genetic diseases with corresponding genes over this packaging limit.”
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Duan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262 · cited 2×
“An alternative method to address packaging limitation is to split the oversized transgenes into two or more segments (Burton et al ., 1999; Yan et al ., 2000, 2007; Duan et al ., 2001; Chao et al ., 2002; Lai et al ., 2005, 2006; Ghosh et al ., 2006, 2011).”
Cited by
The past and future of haemophilia: diagnosis, treatments, and its complications
Peyvandi, F., Garagiola, I., & Young, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01123-x · Cited by 505
Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion
Tuo, Q.-Z., Liu, Y., Xiang, Z., Yan, H.-F., Zou, T., Shu, Y., Ding, X.-L., Zou, J.-J., Xu, S., Tang, F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00917-z · Cited by 330
“The rAAV8 vectors were collected at 72 h post-transfection and purified by two rounds of CsCl gradient ultracentrifugation, followed by silver staining and genome copy titration, as described previously.(100) The viral vectors were aliquoted and stored at - 80 °C before use.”
MethodSelf-citationLange, A. M., Altynova, E. S., Nguyen, G. N., & Sabatino, D. E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.64 · Cited by 78
Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay
Guo, P., Zhang, J., Chrzanowski, M., Huang, J., Chew, H., Firrman, J. A., Sang, N., Diao, Y., & Xiao, W. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.007 · Cited by 33
“rAAV Production and Purification AAV vectors were generated using the triple plasmid co-transfection method, as described previously.(21,22) Briefly, pAAV-Rep-Cap (serotypes 2 and 8), pAd helper, and the transgene plasmids pdsAAVCB-EGFP were co-transfected into HEK293 cells and cultured in roller bottles at a ratio of…”
MethodSelf-citation
Metadata
- Authors
- Wang, Q., Dong, B., Firrman, J., Roberts, S., Moore, A. R., Cao, W., Diao, Y., Kapranov, P., Xu, R., & Xiao, W.
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2014-08
- Volume
- 25
- Issue
- 4
- Pages
- 261-268
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- OpenAlex
- W2330262084
- Cited by
- 35
- References
- 23
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.